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Abstract
Background: The prognosis for patients with breast tumor metastases to brain is extremely poor. Identification
of prognostic molecular markers of the metastatic process is critical for designing therapeutic modalities for
reducing the occurrence of metastasis. Although ubiquitously present in most human organs, large-conductance
calcium- and voltage-activated potassium channel (BKCa) channels are significantly upregulated in breast cancer
cells. In this study we investigated the role of KCNMA1 gene that encodes for the pore-forming α-subunit of BKCa
channels in breast cancer metastasis and invasion.
Methods: We performed Global exon array to study the expression of KCNMA1 in metastatic breast cancer to
brain, compared its expression in primary breast cancer and breast cancers metastatic to other organs, and
validated the findings by RT-PCR. Immunohistochemistry was performed to study the expression and localization
of BKCa channel protein in primary and metastatic breast cancer tissues and breast cancer cell lines. We
performed matrigel invasion, transendothelial migration and membrane potential assays in established lines of
normal breast cells (MCF-10A), non-metastatic breast cancer (MCF-7), non-brain metastatic breast cancer cells
(MDA-MB-231), and brain-specific metastatic breast cancer cells (MDA-MB-361) to study whether BKCa channel
inhibition attenuates breast tumor invasion and metastasis using KCNMA1  knockdown with siRNA and
biochemical inhibition with Iberiotoxin (IBTX).
Results: The Global exon array and RT-PCR showed higher KCNMA1 expression in metastatic breast cancer in
brain compared to metastatic breast cancers in other organs. Our results clearly show that metastatic breast
cancer cells exhibit increased BKCa channel activity, leading to greater invasiveness and transendothelial migration,
both of which could be attenuated by blocking KCNMA1.
Conclusion: Determining the relative abundance of BKCa channel expression in breast cancer metastatic to brain
and the mechanism of its action in brain metastasis will provide a unique opportunity to identify and differentiate
between low grade breast tumors that are at high risk for metastasis from those at low risk for metastasis. This
distinction would in turn allow for the appropriate and efficient application of effective treatments while sparing
patients with low risk for metastasis from the toxic side effects of chemotherapy.
Published: 29 July 2009
BMC Cancer 2009, 9:258 doi:10.1186/1471-2407-9-258
Received: 21 October 2008
Accepted: 29 July 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/258
© 2009 Khaitan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
Page 2 of 11
(page number not for citation purposes)
Background
A significant number of patients in the U.S with metastatic
brain tumors face a dismal prognosis and high mortality.
Increasing numbers of breast cancer patients are being
diagnosed with brain metastases, possibly as a result of
the emergence of targeted and aggressive systemic cancer
therapy. In overall frequency, breast cancers and lung can-
cers are by far the most common cancers that metastasize
to brain [1,2]. Brain metastasis generally arises in women
diagnosed with aggressive breast cancer or in men with
advanced lung cancer. The actual incidence of brain
metastases is not precisely known, however studies sug-
gest that 6–16% of patients with metastatic breast cancer
develop brain metastases during their lifetime. Further-
more, autopsy studies have reported brain metastases in
18–30% of patients dying ofbreast cancer [3]. The major-
ity of women who develop brain metastases have pre-
sented with debilitating neurological symptoms, and have
undergone aggressive treatment for stage IV disease [4-6].
Although brain metastasis is the leading cause of breast
cancer death, its pathogenesis is poorly understood and
the predictors of breast metastasis to brain are yet to be
characterized.
Accumulating evidence suggests that human epidermal
growth factor receptor 2 (HER2) overexpression and con-
sequent trastuzumab (Herceptin)-based therapy might be
associated with a higher rate of brain metastases [7]. Ret-
rospective studies in the U.S. in women with HER2 over-
expressing breast cancer receiving trastuzumab-based
treatment have indicated that approximately one-third of
patients had developed brain metastases [7-9]. Palmeri et
al. suggested that HER2 overexpression increases meta-
static outgrowth of breast cancer cells in the brain [10],
and that HER2 overexpression might be a predictor of
asymptomatic, occult brain cancer. Therefore, it is
extremely important to study the genetic changes in breast
cancer cells that lead to brain metastasis and to develop
specific targeted molecular agents. Many genetic aberra-
tions are reported in human breast cancers, including
altered splice variants and loss of genomic imprinting.
Specifically, altered BKCa  channels, which respond to
changes in intracellular calcium and membrane potential,
are described in a wide variety of tumor cell types. For
example, Huang [11] reported that p21ras plays a pivotal
role in controlling oncogenic transformation [12], and
with its immediate downstream target, Raf kinase, is
required for the induction of BKCa channels. Although
ubiquitously present in most human organs, the pore
forming α-subunit of the BKCa channel is encoded by the
KCNMA1  gene, and is significantly unregulated and
altered in cancer cells. In human glioma cells, up-regula-
tion and constitutive activation of the KCNMA1 gene and
its alternate splice variants are correlated with increased
malignancy [13]. Up-regulation of BKCa  channels was
shown to be a novel mechanism for the malignant pheno-
type of human tumor cells [14]. However, in osteosar-
coma, KCNMA1 was shown to have antitumor property,
suggesting that KCNMA1 may have diverse roles in differ-
ent tumor types [15].
In the present study, our results from global exon array
analysis showed higher expression of KCNMA1 in meta-
static breast cancers located in brain than in metastatic
breast cancers in other organs. This observation prompted
us to investigate the potential for invasiveness and brain
metastasis of KCNMA1 expression in normal breast cells
(MCF-10A), non-metastatic breast cancer (MCF-7), non-
brain metastatic breast cancer cells (MDA-MB-231), and
brain specific metastatic breast cancer cells (MDA-MB-
361). Our results clearly show that metastatic breast can-
cer cells exhibit increased BKCa channel activity, leading to
greater invasion and transendothelial migration. We
showed that the invasion and transendothelial migration
of breast cancer cells can be attenuated by blocking BKCa
channel activity. Therefore, determining the relative abun-
dance of KCNMA1 in breast cancer metastases to brain
and understanding its role in brain metastasis may allow
us to target KCNMA1 for its prognostic and possibly ther-
apeutic potential.
Methods
Cell lines and patient tissue samples
Established cell lines representing normal breast (MCF-
10A), non-metastatic breast cancer (MCF-7, ER positive),
non-brain metastatic breast cancer (MDA-MB-231, ER
negative), and brain-specific metastatic breast cancer
(MDA-MB-361, ER positive) were obtained from the
American Type Culture Collection (Manassas, VA) and
maintained as per ATCC guidelines. The established
human brain microvasculature endothelial cell line
(HCMEC/D3) of normal brain endothelial phenotype,
kindly provided by Dr. Weksler (Weill Medical College,
Cornell University, NY), was used to study transendothe-
lial migration of the breast cancer cell lines [16]. Normal
breast and breast tumor tissues were obtained from
Memorial Health University Medical Center (MHUMC)
and Comprehensive Human Tissue Network, University
of Alabama according to the protocol approved by
MHUMC Institutional Review Board.
Exon Array
Total RNA from exponentially growing breast cancer cell
lines was extracted and purified using TRIzol reagent (Inv-
itrogen) and RNeasy columns (Qiagen). Single-stranded
cDNA was generated from the amplified cRNA with the
WT cDNA Synthesis Kit (Affymetrix), fragmented and
labeled with the WT Terminal Labeling Kit (Affymetrix).
Samples were hybridized with GeneChip Human Exon
1.0 ST Arrays (Affymetrix) and scanned at the MemorialBMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
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Health University Medical Center Genomics Core Facility.
Intensity values were deposited with the GEO database
http://www.ncbi.nlm.nih.gov/geo under the accession
number GSE17019. Data was subjected to background
correction and normalized using Expression Console
(Affimetrix). Gene level expression values (probeset
intensity analysis) were derived using RMA algorithm
using core annotation level for transcripts. Exon array data
was further analyzed using Partek Genomic Suite 6.4 soft-
ware (Partek Inc., St. Louis, MO). Gene-level data was
then filtered to include only those probesets that are in the
'core' meta-probe list, which represents RefSeq genes and
full-length GenBank mRNAs. Analysis of Variance
(ANOVA) and multi test correction for P-values in Partek
Genomic Suite were used to identify differentially
expressed genes, using tissue type (primary versus meta-
static tissue) as the candidate variable in the ANOVA
model to obtain metastatic specific genes.
RNA extraction and PCR
Total RNA was extracted from cells which were 75% con-
fluent and from the frozen tissues disrupted using a
dounce homogenizer and extracted with TRIzol. The con-
centration of RNA was determined using a NanoDrop
Spectrophotometer (NanoDrop Technologies, USA).
cDNA for RT-PCR was generated by the SuperScript™ First-
Strand Synthesis System according to manufacturer's
instructions (Invitrogen). PCR was carried out in a total
volume of 20 μl, containing 0.2 mM dNTPs, 1 mM MgCl2
and 1 Unit of AmpliTaq Gold DNA Polymerase (Applied
Biosystem). Thirty two amplification cycles were per-
formed (Applied Biosystem Thermal Controller), using a
denaturing temperature of 95°C for 20 sec, an annealing
temperature of 58°C for 30 seconds, and primer exten-
sion at 72°C for 20 sec. Each amplification experiment
also included two negative PCR controls, a no-RNA con-
trol from reverse transcription procedures and a no-cDNA
water control. Following amplification, 20 μl of the sam-
ples were separated via electrophoresis on a 2% agarose
gel. The primers used for amplification of BKCa channel
were – (5'-TGCAAAGGAG GTTATAAAGTTACG-3' and 5'-
ATTTCACAAAAGTTTTCACAAGGAC-3').
BKCa channel expression and localization in cell lines
Immunostaining of BKCa channel protein was performed
on paraformaldehyde fixed cells, which were permeabi-
lized with 0.05% Triton-X 100 in Phosphate buffer saline
(PBS) for 8 min on ice. After washes with PBS, cells were
incubated with primary antibody (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA) diluted 1:400 in PBS containing
1% horse serum, 2% bovine serum albumin (BSA), and
0.05% Triton-X 100 for 30–45 minutes at 4°C. Cells were
then washed with PBS containing 1% horse serum and
2% BSA, and incubated with fluorescein isothiocyanate
(FITC)-labeled goat anti-rabbit IgG1 secondary antibody
(Sigma) diluted 1:500 in PBS containing 1% horse serum,
2% BSA, and 0.05% Triton-X 100 for 60 min at 4°C. BKCa
channel green (FITC) fluorescence was recorded for a
minimum of 5,000 events using a Guava flow cytometer.
Images for localization of BKCa  channel protein were
acquired using a Nikon Eclipse TE 2000U inverted micro-
scope fitted with a fluorescence filter for FITC, Photomet-
rics coolsnap HQ2 charge couple device camera, and
Metamorph software.
BKCa channel expression and localization in tumor tissues
To test immunohistochemical expression of BKCa channel
α subunit protein, either fresh-frozen or paraffin-embed-
ded tissues (breast metastasis to brain and one primary
breast cancer tissue) were used. Fresh-frozen tumor speci-
mens stored at -80°C were embedded in OCT (Tissue-Tek,
Miles Laboratories, Elkhart, IN). Cryostat sections were
cut at 10–12 μm thickness, mounted on lysine-coated
glass slides, and fixed for 10 min at 4°C in 4% formalde-
hyde. This step was followed by a 5 minute rinse with PBS
at pH 7.3. Slides were then blocked in blocking buffer
(1% horse serum, 2% BSA, and 0.05% Triton-X 100) for 1
hour at 4°C to decrease nonspecific IgG binding. The sec-
tions were next incubated in a humid chamber at 4°C
overnight with the primary antibodies, anti-BKCa channel
(rabbit) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
diluted 1:1000 in blocking buffer, or with PBS as a nega-
tive control. After 2 washes with PBS, the slides were
stained with anti rabbit FITC conjugated secondary anti-
body.
To study BKCa  channel immunoreactivity in paraffin-
embedded tumor specimens, sections were deparaffinized
with three washes in xylene for 5 minutes each followed
by rehydration with decreasing concentrations of ethanol.
Following this, sections were heated in a water bath (30
minutes at 80°C) in citrate buffer for antigen retrieval.
Then, they were washed in phosphate-buffered saline for
10 minutes and incubated with blocking buffer for 1 hour
before the slides were incubated overnight at 4°C with the
primary antibody rabbit anti-BKCa  channel diluted as
above in blocking buffer or with PBS as a negative control.
After 2 washes with PBS, the localization of BKCa channels
in the tissue sections was studied after staining with anti
rabbit FITC conjugated secondary antibody.
Hematoxylin and eosin staining: Cryosections of breast
tumors were stained with hematoxylin and eosin and
examined by light microscopy.
siRNA studies
The functional activity and biological role of KCNMA1 in
breast cancer cells was studied by transiently knocking
down the KCNMA1 gene using an Ambion Silencer siRNA
transfection II kit. Transfection complexes were preparedBMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
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in Opti-MEM serum-free medium (Invitrogen) by mixing
0.3 μL of siPORT NeoFX Transfection Reagent (Ambion)
and 30 nM of siRNA (silencer pre designed siRNA
AM16708A from Ambion). Breast cancer cells (8000 cells/
well) were plated in 96-well plates simultaneously with
addition of transfection complexes for membrane poten-
tial assays while 6-well plates (45,000 cells/well) were
used for other studies. Cells were incubated for 72 h, and
subsequently used for various assays.
Membrane Potential Assay
The functional activity of BKCa channels in breast cancer
cells was measured using the FLIPR Membrane Potential
Assay Kit on the FLEXstation (Molecular Devices, Sunny-
vale, CA) as described previously [17]. This kit provided a
fast, simple and consistent mix-and read procedure and
has the potential to examine the functional characteristics
of ion channels using changes in fluorescence. The BKCa
channel is one such ion channel, whose activation results
in increase of membrane potential due to the opening of
a K+-permeant, cation-selective channel leading to a
decrease in fluorescence. Briefly, the cells were seeded in
sterile, clear flat bottom, 96-well plates (Corning Inc.,
MA) at a density of 4 × 104 cells/well and cultured to
achieve a monolayer within 48 hr. The monolayer of cells
was incubated with the membrane potential assay rea-
gents for 30 min before loading the test compounds. The
anionic potentiometric dye that traverses between cells
and extracellular solution in a membrane potential-
dependent manner serves as an indicator of voltage
changes across the cell membrane. Dose response studies
were performed with 0 to 100 μM 1-(5-chloro-2-hydroxy-
phenyl)-5-trifluoromethyl-1,3-dihydro-2-benzimidazol-
2-one (NS-004) (Neurosearch NA, Denmark) with or
without Iberiotoxin (IBTX; 10 nM) (Sigma, St. Louis,
MO). The FLEXstation was set up using the following
parameters: excitation: 530 nm, emission: 565 nm and
emission cut off: 550 nm wavelenghs. Observations and
recordings were made for 300 seconds after adding NS-
004 and IBTX.
Matrigel Invasion
BD BioCoat™ growth factor reduced insert plates
(Matrigel™ Invasion Chamber 12 well plates) were pre-
pared by rehydrating the BD Matrigel™ matrix coating in
the inserts with 0.5 ml of culture medium for two hours at
37°C. The rehydration solution was carefully removed
from the inserts, 0.75 ml DMEM containing chemo-
attractant (1%FBS) was added to the lower wells of the
plate, and 0.5 ml of cell suspension (2.5 × 104 cells, in
serum-free medium containing 0.1%BSA) was added to
each insert well. For invasion inhibition assays IBTX (10
nM) was added to the cell culture medium in both upper
and lower chambers along with cells and chemo-attract-
ant solution. Cells transiently transfected with siRNA for
the KCNMA1 gene was also plated to confirm our results
obtained with IBTX. Untreated cells were included as
migration controls, were used without rehydration. Inva-
sion assay plates were incubated for 20–22 hours at 37°C.
Following incubation, the non-invading cells were
removed by scrubbing the upper surface of the insert. The
cells on the lower surface of the insert were stained with
crystal violet and each transwell membrane mounted on a
microscopic slide for visualization and analysis. The
number of tumor cells that had migrated from the upper
to the lower side of the filter was counted by an individual
blinded for the study using a phase-contrast microscope
in the central area of the filter. Data are expressed as the
percent invasion through the membrane relative to the
migration through the control membrane.
% invasion = Mean number of treated cells invading
through the matrigel insert membrane/Mean number of
untreated cells migrating through membrane
Transendothelial Migration
The invasion of cancer cells through a monolayer of brain
endothelial cells is considered to represent the trans-cellu-
lar migration activity of the cancer cells. Basic insights into
metastasis to brain have been obtained through experi-
ments using human umbilical vein endothelial cells
(HUVECs). However, endothelial cells from different vas-
cular beds are uniquely adapted to meet the demands of
the underlying tissues [18], and data from HUVECs are
not directly applicable to breast tumor cell interaction
with endothelial cells at the blood brain barrier (BBB). In
this regard, differences between HBMVECs (human brain
microvscular endothelial cells) and HUVECs have been
reported [18]. We therefore used HCMEC/D3 cells, which
are derived from human brain microvasculature to study
transendothelial migration of breast tumor cells to brain.
HCMEC/D3 cells were seeded at a density of 2 × 105 cells/
dish on 35-mm plastic culture dishes coated with collagen
and allowed to grow for 4 days to form a confluent mon-
olayer. After the monolayer of HCMEC/D3 has been
rinsed once with fresh culture medium, NS-004, IBTX and
siRNA- treated breast cancer cells were seeded on top of
the HCMEC/D3 at a density of 5 × 104 cells/dish. Follow-
ing co-incubation for 16 hourat 37°C, non-adherent cells
were removed by aspiration and the remaining cell layer
was fixed in 10% formalin in PBS. The number of cancer
cells that had penetrated the monolayer as well as cancer
cell colonies (collectively called invasion foci) was
counted under a phase-contrast microscope in 16 differ-
ent visual fields. Data were expressed as percentage migra-
tion of treated breast cancer cells compared with
migration of untreated controls, presumably metastatic to
brain since the cancer cells were co-cultured with human
brain microvascular endothelial cells.BMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
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Results
Exon array and PCR
The data obtained by the GeneChip Exon array (Affyme-
trix) demonstrated that the KCNMA1  gene was over-
expressed in breast cancer cell lines derived from human
breast cancer metastases to brain (MDA-MB-361) as com-
pared to metastatic breast cancer cells derived from sys-
temic organs (MDA-MB-231) or primary breast cancer
(MCF-7) (Figure 1). To study if differential expression of
KCNMA1 occurs in vivo in different tissues, a series of
specimens of fresh frozen and paraffin-embedded pri-
mary breast cancer, breast tumor metastases to different
organs of the body and brain were analyzed by semi-
quantitative RT-PCR. The PCR results were consistent with
the microarray findings (Figure 2). Expression of the
KCNMA1  gene was higher in breast tumor specimens
from brain metastases compared to specimens from pri-
mary breast cancer or metastases to other organs. Similar
results were also obtained using breast tumor cell lines of
known metastatic predilection. These results imply that
overexpression of KCNMA1 gene may likely be associated
with breast cancer cells that metastasize to brain.
Localization and expression of BKCa channel protein
Immunostaining was performed to localize BKCa channel
protein in breast cancer cells. Expression of the BKCa chan-
nel was primarily confined to the plasma membrane (Fig-
ure 3A). Staining with affinity-purified anti-BKCa channel
antibody also revealed higher expression of BKCa channel
protein in MDA-MB-361 cells compared to MCF-10A,
MCF-7 or MDA-MB-231 cells (Figure 3A). Control experi-
ments with cells negative for BKCa channels demonstrated
lower protein signal intensity, indicating the specificity of
the antibody (data not shown). In other supporting exper-
iments, the mean fluorescence intensity (MFI) of BKCa
channel protein was 187 in MDA-MB-361 cells compared
to 13 in MCF-10A, 46 in MCF-7, and 79 in MDA-MB-231
cells (Figure 3B). These results demonstrate the presence
of different levels of BKCa channel protein expression in
different breast cancer cell lines evaluated.
Expression of BKCa channel protein is not only restricted
to cell lines but also present in human breast cancer tis-
sues. Immunofluorescence performed on human breast
cancer tissue revealed very few cells expressing BKCa chan-
nel on primary breast cancer tissue (Figure 3C:a), while a
moderate number of cells expressed BKCa channel protein
in breast cancer metastatic to different organs (Figure
3C:b). In agreement with the previous reports almost all
the breast cancer cells metastatic to brain robustly
expressed BKCa channel protein (Figure 3C:c).
Membrane potential
Immunolocalization and protein expression studies
showed increased BKCa channel expression in MDA-MB-
361 cells as compared to MCF-7 or MDA-MB-231. We per-
formed membrane potential studies to determine
Expression of KCNMA1 gene using Affymetrix Genechip  Exon Array Figure 1
Expression of KCNMA1 gene using Affymetrix Gene-
chip Exon Array. mRNA expression of KCNMA1 was sig-
nificantly enhanced in the MDA-MB-361 (brain metastatic) 
cancer cell line as compared to the MCF-7 (non metastatic) 
and MDA-MB-231 (systemic metastatic) cell lines. MCF-7 (P 
< 0.0002) and MDA-MB-361(*P < 0.0001), (n = 3 per cell 
line).
Analysis of KCNMA1 gene expression by RT-PCR Figure 2
Analysis of KCNMA1 gene expression by RT-PCR. 
Semiquantitative RT-PCR analyses of human primary breast 
cancer (n = 6), metastatic breast cancer {n = 6, sample 1 
(metastasized to ovary), 2 and 3 (metastasized to liver), 4–6 
(metastasized to lymph node)}, metastasized to brain (n = 4) 
and breast cancer cell lines reveals differential expression of 
KCNMA1 gene expression (α-subunit, 250 bp). GAPDH was 
used as the loading control. NB: Normal breast tissue, MCF-
10A (normal breast cell line), MCF-7 (non mets), 231: MDA-
MB-231 (Mets) and 361: MDA-MB-361 (Brain Mets). Note: 
Only one of six primary breast cancer tissues showed detect-
able amount of KCNMA1 RNA (see arrow).BMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
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whether the overexpressed BKCa channels show increased
functional activity using the FLIPR Membrane Potential
Assay kit on the FLEX station. Hyperpolarization is
reflected as decrease in fluorescence at 565 nm. A specific
BKCa channel activator, NS-004, was added to the cells in
a dose-dependent manner, and an optimum concentra-
tion of 50 μM was established (data not shown), for fur-
ther studies. All the four breast cancer cell lines listed
above showed hyperpolarization after the addition of NS-
004 and the effect lasted for more than 300 seconds. The
hyperpolarizing action of NS-004 was most marked in
MDA-MB-361 cell lines (Figure 4) compared to other
breast cancer cell lines. These results demonstrate that
BKCa channels in MDA-MB-361 and other breast cancer
cell lines were functional. IBTX (10 nM), a BKCa channel
antagonist, blocked the membrane hyperpolarization in
all the breast cancer cells tested. In addition, transient
silencing of functional BKCa channels by siRNA was per-
formed. After testing different concentrations of siRNA
(10–75 nM) 30 nM was determined to be optimum (>30
nM was toxic to cells, data not shown). Exposure of the
breast cancer cells lines to 30 nM siRNA inhibited NS-004
induced activity of BKCa channels by 65–70% in MCF-10A
and MCF-7, and 75–85% reduction MDA-MB-231 and
Localization and expression of BKCa channel protein Figure 3
Localization and expression of BKCa channel protein. A: Immunofluorescence of breast cancer cell lines stained for 
BKCa channel (green) and nuclei with DAPI (blue). Expression of BKCa channel was strong in MDA-MB-231 and MDA-MB-361, 
weak in MCF-7 and indiscernible in MCF-10A. Stains were repeated twice. B: Flow cytometric detection of BKCa channel pro-
tein expression in various breast cell lines. Representative histograms from (a) MCF-10A, (b) MCF-7, (c) MDA-MB-231, and (d) 
MDA-MB-361 showing expression of BKCa channel protein. C: Immunofluorescence of anti-BKCa channels antibody on human 
breast cancer tissue. Antibody labeled in green (FITC), nuclei counterstained in blue (DAPI). (a) Very few cells show BKCa chan-
nels staining in the primary breast cancer tissue (n = 6, See large arrow). Note: Absence of green staining in most of the cells 
also indicates specificity of the antibody (See small arrows). (b) Systemic metastatic breast cancer (lymph node) shows an 
increased number of cells stained with BKCa channel antibody (n = 6; See large arrows). (c) All breast cancer tissue metastatic 
to the brain are strongly positive for the BKCa channels (n = 4). Magnification = 400×. D: Representative H&E staining of breast 
tumor tissue sections.BMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
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MDA-MB-361 cells (Figure 4, dark bars). These data indi-
cate that BKCa channel activity is functionally distinct in
the four breast cancer cell lines studied, being highest in
the line that metastasizes preferentially to brain, and can
be silenced by a specific BKCa channel inhibitor such as
IBTX or by treatment with siRNA.
BKCa channel inhibition and effect on breast cancer cell 
invasiveness
BKCa channels are known to enhance the invasion of
tumor cells. Therefore, we studied the effect of increased
activity of BKCa channels on the invasion of breast cancer
cells into Matrigel-coated membranes in a Transwell
chamber. No invasion was observed with MCF-10A cells,
while MDA-MB-361 cells were more invasive than MCF-7
or MDA-MB-231 cells (Figure 5A). Interestingly the
enhanced invasiveness of MDA-MB-361 cells was inhib-
ited by only 50% by IBTX while invasion of MCF-7 was
inhibited by 80% by IBTX (Figure 5B) suggesting that
BKCa channels may play a greater role in the invasion of
MCF-7 cells. Furthermore, treating cells with siRNA that
targeted the KCNMA1  gene inhibited the invasion of
breast cancer cell lines to a similar extent as did treating
them with IBTX (Figure 5B). These results clearly suggest
that BKCa channels may play a role in invasion of breast
cancer cells because inhibition of BKCa channels signifi-
cantly attenuated the invasion process.
Transendothelial migration (TEM) of breast cancer cells
The effect of IBTX and siRNA on the capacity of breast can-
cer cells to invade a human brain microvascular endothe-
lial cell monolayer (HCMEC/D3) in vitro was measured by
a TEM assay as described by Kusama et al [19]. Non-brain
metastatic breast cancer cells (MDA-MB-231) showed 65–
70% less TEM than did brain metastatic breast cancer cells
(MDA-MB-361) (Figure 6A), while normal breast epithe-
lial cells (MCF-10A) did not show detectable TEM. IBTX
inhibited the TEM of MCF-7 cells by 48% and migration
of MDA-MB-361 cells by 69% (Figure 6B). The inhibition
of TEM was similar when siRNA was used to suppress
expression of the KCNMA1 gene (Figure 6B). These results
clearly demonstrate that either chemical or biological
inhibition of BKCa channels might significantly decrease
breast cancer metastasis to brain.
Discussion
Genetic damage or alteration of primary tumor character-
istics potentiates cancer metastasis to distant organs
including brain. Tumor metastasis is a clonally selective
process that occurs as part of tumor progression, a concept
that has been supported by experimental [10] and clinical
research. Generally, breast cancer metastasis is the hall-
mark of an aggressive tumor, resistant to treatment.
Molecular factors that may contribute to organ-specific
metastasis of breast cancer to lung and bone have been
identified [20,21]. However, it is not clear how and why
certain patients with primary breast cancers develop brain
metastases, while in other patients tumors remain con-
fined to the primary sites. Recent investigations in patients
with metastatic lung and breast cancers reported alarming
rates of brain metastases in both instances. For example,
among metastatic breast cancer patients with HER2 posi-
tive tumors, the incidence of brain metastases varied from
26% to 48% (8–12). The brain and its supporting struc-
tures represent a unique environment for metastatic
growth. Molecular factors contributing to the survival of
tumor cells in metastatic lesions may be organ specific
and could further influence the tumor cells with respect to
their gene and protein expression, growth dynamics, and
non-responsiveness to treatment. Unraveling the mecha-
nism that drives the metastatic machinery in these cancer
cells may offer insights into how to limit or potentially
prevent this lethal process.
We showed that the biochemical opening of BTB with
BKCa channel modulators increases the BTB permeability
and enhance delivery of hydrophilic therapeutic drugs or
small- to large-sized molecules, anti-tumor compounds,
therapeutic proteins and viral vectors in vivo to brain
Differential BKCa channel activity measured by membrane  potential in breast cancer cell lines Figure 4
Differential BKCa channel activity measured by mem-
brane potential in breast cancer cell lines. The BKCa 
channel activity was measured in the presence of its activator 
NS-004 with and without siRNA for KCNMA1 gene. Pretreat-
ment of breast cancer cell lines with siRNA significantly (*p < 
0.046; **p < 0.001) inhibited the BKCa channel activity follow-
ing addition of NS-004. Note: Decreased drop in fluorescence 
(indicator of BKCa channel opening/activity) of siRNA + NS-
004- treated cells compared to NS-004 treated cells demon-
strates that BKCa channel activity was inhibited by addition of 
siRNA to cells, as fluorescence quenching is an indirect 
measure of K+ ion-mediated hyperpolarization (hyperpolari-
zation is caused by efflux of K+ through K+ channels), shown 
in the Y-axis. Bars represent the mean and standard error of 
the mean obtained from three different experiments in tripli-
cate (n = 9).BMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
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tumors selectively with little or no drug delivery to normal
brain [17,22-24].
Increasingly, targeted molecular therapy is gaining popu-
larity, especially the use of humanized monoclonal anti-
bodies. Although targeting oncogenes expressed on tumor
cells is one viable cancer treatment strategy, oncologists
often need to target additional molecules related to tumor
stroma that promote tumor metastasis and growth. We
used gene expression profile study to identify increased
KCNMA1 expression in a breast cancer cell line metastatic
to brain (MDA-MB-361) (Figure 1) as compared to
expression in a primary, breast cancer cell line (MCF-7) or
breast cancer cell line metastatic to other organs (MDA-
MB-231) of the body but not to brain. Others have shown
an up-regulation of BKCa channels as a novel mechanism
for producing the malignant phenotype of human tumor
cells [14]. Our results clearly demonstrate that the
KCNMA1  is upregulated in the MDA-MB-361 cell line
(Figure 1). RT-PCR data (Figure 2) from tumor tissues and
from breast cancer cell lines further supported these find-
ings, suggesting a close association between level of BKCa
channel expression and metastasis to brain. In agreement
with the PCR results on breast cancer cell lines, immuno-
cytochemistry results showed strong expression of BKCa
channels in MDA-MB-361 cells (Figure 3A) as compared
to MCF-10A cells (Figure 3A). The presence of the BKCa
channel protein was also confirmed using flow cytometry
(Figure 3B). The immuno staining of the sections from
human breast cancer tissue indicated that BKCa channel
protein expression was pervasive in metastatic brain
tumors (Figure 3C:c) compared to primary cancers and
those metastatic to other organs (Figure 3C:a&b). In addi-
tion, we showed that BKCa channel is pharmacologically
functional by knocking down the KCNMA1  gene with
siRNA, which has led to a decrease in activity (drop in flu-
orescence) in all the cell lines studied (Figure 4). The BKCa
channel activation was 3-fold higher in breast cancer cells
metastatic to brain (MDA-MB-361) than in normal breast
cells (MCF-10A) (Figure 4). These results confirm higher
expression of BKCa channels on brain specific metastatic
breast cells (MDA-MB-361) than in normal breast cells
and non-brain metastatic breast cancer cells (MDA-MB-
231). These findings corroborate the immunostaining
data (Figure 3A) and are consistent with our previous
studies showing overexpression of BKCa channels in glio-
KCNMA1 expression promotes breast cancer cell invasion Figure 5
KCNMA1 expression promotes breast cancer cell invasion. A: Representative images of breast cancer cells that have 
migrated through the Matrigel coated transwell and adhered to the lower surface of the filters. The migrated cells were stained 
with crystal violet (see arrows). B: Breast cancer cells pretreated with IBTX or siRNA to silence the KCNMA1 gene demon-
strated significantly (*P < 0.03; **P < 0.001) reduced BKCa channel mediated invasion compared to untreated breast cancer cell 
lines. Data are expressed as percentage of migration in the untreated controls (100%). Bars represent mean ± the standard 
error of the mean obtained from three different experiments (n = 3).BMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
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mas and in endothelial cells surrounding malignant brain
tumors [17]. Other investigators have also demonstrated
over expression of BKCa  channels to correlate with
increased malignancy of human gliomas [25]. Other type
of K+ channel (KCNK9) was also shown to have oncogenic
properties in breast cancer [26]. Taken together our data
suggest that there may be an association between BKCa
channel overexpression and breast cancer metastasis to
brain.
The most recent electrophysiological information about
BKCa channels came from studies on vertebrate cells with
the patch clamp [27]. The cDNAs of BKCa channels have
been cloned, and its 7-transmembrane topology has been
identified. The N-terminus of BKCa channels is in the
extracellular space because an additional transmembrane
segment called S0 precedes the canonical S1 through S6
transmembrane segments. With fixed level of intracellular
Ca2+ [Ca2+]i, BKCa channels behave like delayed-rectifier
K+ channels, activating with depolarization where the gat-
ing rates and the resulting probability of being open are
also sensitive functions of [Ca2+]i.
Various therapeutic suggestions have been made by inves-
tigators based on genome-wide expression analysis of
breast cancers, such as adjusting the intensity of current
chemotherapy based on cancer subtypes as defined by
gene expression signatures [28]. Unfortunately, because a
large number of genes with many diverse functions are
identified as prognostic signatures, the lists of genes may
yield excellent prognostic markers without revealing
much of the underlying biological mechanisms thereby
providing little guidance for a course of action. In contrast
our study showed that inhibition of BKCa channels using
either a siRNA or specific chemical inhibitor significantly
reduces in vitro the invasive capability of the breast cancer
cell lines (Figure 5). This finding further requires valida-
tion in biological tumor models. Surprisingly the decrease
in the invasive capability of MCF-7 following the addition
of BKCa channel inhibitor IBTX was greater than that
observed in MDA-MB-361 cells. One possible explanation
could be that MDA-MB-361 cells are HER2 positive,
which may induce the breast cancer cells to metastasize to
brain. Furthermore, HER2 expression may skew the BKCa
channel induced invasiveness of MDA-MB-361 cells,
Effects of IBTX and siRNA on transendothelial migration of breast cancer cells Figure 6
Effects of IBTX and siRNA on transendothelial migration of breast cancer cells. A: Representative images of breast 
cancer cells that adhered to monolayer of the human brain microvasculature endothelial cell line HCMEC/D3. The adherent 
breast cancer cells appear white in color against the background of HCMEC/D3. (See arrows). B: Breast cancer cells pre-
treated with IBTX or siRNA to silence the KCNMA1 gene demonstrated significantly (*P < 0.05; **P < 0.001) reduced BKCa 
channel mediated-TEM of breast cancer cells across HCMEC/D3 monolayer compared to untreated control. Data is presented 
as percentage migration of treated breast cancer cells compared with migration of untreated controls (100%); Bars represent 
the mean ± standard error of the mean obtained from three different experiments (n = 3).BMC Cancer 2009, 9:258 http://www.biomedcentral.com/1471-2407/9/258
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while MCF-7 (HER2 negative) cells may depend predom-
inantly on BKCa channels for invasion.
The unique properties of the brain may explain the pro-
pensity of certain breast cancer cells to metastasize to the
brain. Specifically the brain vascular endothelial cells
forming the BBB are significantly different from the sys-
temic endothelial cells [29]. A key event in brain metasta-
sis is TEM of breast cancer cells. We examined whether
inhibition of BKCa channels expressed in breast cancer
cells metastatic to brain, prevents TEM of MCF-7, MDA-
MB-231, and MDA-MB-361 cells across the monolayer of
HCMEC/D3 cells. As anticipated, targeting KCNMA1 with
siRNA or BKCa channels with IBTX significantly decreased
the TEM of MCF-7, MDA-MB-231, and MDA-MB-361 cells
across the monolayer of HCMEC/D3 (Figure 6). Most
importantly a normal breast cell line (MCF-10A) did not
exhibit TEM even when the BKCa channels were activated
with NS-004 (data not shown). Our data suggest that
increased TEM, at least in part, requires increased BKCa
channel expression and/or activity. Thus, blocking BKCa
channel function potentially may delay or prevent breast
cancer metastasis to the brain. In summary, we showed
that BKCa channels are overexpressed in breast cancer cells
metastatic to brain. The high expression level correlated
with BKCa channel activity, invasion and TEM of the breast
cancer cells metastatic to brain.
Conclusion
Tumor metastasis is a complex and highly regulated proc-
ess involving multiple tumor-host interactions. Accurately
determining breast cancer's risk of metastasis to other
organs including brain will improve the capacity of clini-
cians to decide on optimal patient management. Identify-
ing organ-specific KCNMA1 gene involved in metastatic
process, and developing targeted therapies against
KCNMA1 will hopefully lead to better treatments for this
deadly metastatic disease. Furthermore, advances in the
identification of contributing factors including the role of
KCNMA1 in the metastatic processes, as well as under-
standing its function and regulation may result in the
development of targeted agents to suppress BKCa channel
over expression in breast cancers.
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